Boehringer Ingelheim Recalls Catapres Tablets Due to Dissolution Testing Anomaly
Boehringer Ingelheim is recalling specific Catapres tablets because an extraneous peak was observed during dissolution testing. The recall covers products distributed nationwide and in Puerto Rico.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses or injuries. The hazard is a testing anomaly without confirmed harm, fitting the criteria for a moderate severity score.
Plain-English summary
Boehringer Ingelheim Pharmaceuticals, Inc. is recalling Catapres (clonidine hydrochloride, USP) 0.2 mg tablets. The recall is limited to 100-count bottles with NDC 0597-0007-01, Lot # 861135, C34139, and an expiration date of November 2021.
The recall was initiated because an extraneous peak was observed during dissolution testing. The source text does not specify the nature of the peak or the potential clinical impact. The affected products were distributed nationwide in the USA and Puerto Rico.
Consumers and healthcare providers should check their inventory for the specific lot and expiration date listed above. The source text does not provide specific instructions for disposal or return, nor does it report any illnesses or injuries associated with the product.
The recalled product
- Product
- Catapres (clonidine hydrochloride, USP) 0.2 mg, tablet, 100-count bottle, Rx only, Dist. by: Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT 06877, Made in Germany, NDC, 0597-0007-01
- Manufacturer
- Boehringer Ingelheim Pharmaceuticals, Inc.
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot # 861135
- C34139
- EXP Nov 2021
Distribution
Part of a larger recall action
This product is one of 3 recalled by Boehringer Ingelheim Pharmaceuticals, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Boehringer Ingelheim Pharmaceuticals, Inc.
See all →- ModerateSynjardy XR Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2026-07-08
- HighPrescription Drug Recall: Jardiance Empagliflozin 25 mg Label Mix-Up
FDA (Drugs) · 2023-03-29
- ModerateMicardis (Telmisartan) 80 mg Tablets Recall Due to Subpotency
FDA (Drugs) · 2021-06-09
- ModerateBoehringer Ingelheim Recalls Catapres Tablets Due to Dissolution Testing Anomaly
FDA (Drugs) · 2020-11-04
- ModerateBoehringer Ingelheim Recalls Catapres Tablets Due to Dissolution Testing Anomaly
FDA (Drugs) · 2020-11-04
Same hazard · quality control
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateDuoGlide Short-Term Dialysis Catheter recall due to deficient manufacturing
FDA (Devices) · 2026-07-08
- ModeratedirectCHECK whole blood control labeled with incorrect performance range
FDA (Devices) · 2026-06-24
- HighAmyloid plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11
- HighpTau 217 plasma controls recalled over falsely elevated ratio results
FDA (Devices) · 2026-02-11